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Abstract The present study underlines the importance of
phosphatidylinositol 3-kinase (PI 3-kinase) in attenuating the
induction of nitric oxide synthase (iNOS) in human astrocytes.
Proinflammatory cytokines induced the production of nitric
oxide (NO) and the expression of iNOS in human U373MG
astrocytoma cells and primary astrocytes. Expression of a
catalytically active p110 subunit (p110*) of PI 3-kinase but not
that of a kinase-deficient mutant of p110 (p110-kd) induced an
increase in PI 3-kinase activity and inhibited cytokine-induced
production of NO and expression of iNOS. However, expression
of p110* had no effect on the activation of NF-kB, suggesting
that p110* inhibits the expression of iNOS without inhibiting the
activation of NF-kB.
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1. Introduction
A series of proin£ammatory cytokines including interleu-
kin-1L (IL-1L), tumor necrosis factor-K (TNF-K) and interfer-
on-Q (IFN-Q) activate glial cells (astrocytes and microglia) in
the central nervous system (CNS) to induce the expression of
inducible nitric oxide synthase (iNOS) [1^4]. Nitric oxide
(NO) produced by iNOS is of particular importance in path-
ophysiologies of in£ammatory neurological diseases including
demyelinating disorders (e.g. multiple sclerosis, experimental
allergic encephalomyelitis, X-adrenoleukodystrophy) and in
ischemia and traumatic injuries associated with the produc-
tion of proin£ammatory cytokines [5^7]. Astrocytes in the
healthy brain do not express iNOS but following ischemic,
traumatic, neurotoxic or in£ammatory damage, the reactive
astrocytes express iNOS in the mouse, rat and human [1^4].
Characterization of intracellular pathways required to
transduce the signal from the cell surface to the nucleus for
the induction of iNOS is an active area of investigation. Phos-
phatidylinositol 3-kinase (PI 3-kinase), a dual protein and
lipid kinase, is a key signaling molecule implicated in the
regulation of a broad array of biological responses including
receptor-stimulated mitogenesis, oxidative burst and cell sur-
vival [8,9]. PI 3-kinase is composed of a 110 kDa catalytic
subunit (p110) associated with an 85 kDa regulatory subunit
(p85). The p85 regulatory subunit acts as an interface by
interacting with the IRS-1 through its SH2 domain and thus
recruits the p110 catalytic subunit to the cell membrane
through its SH2 domain [8,9]. The p110 then catalyzes the
reaction to release phosphatidylinositol (3,4,5)-triphosphate
as the second messenger using phosphatidylinositol (4,5)-bis-
phosphate as the substrate and activates downstream signal-
ing molecules like Akt/protein kinase B and p70 ribosomal S6
kinase [8,9]. Recently, we have found that inhibition of PI
3-kinase by either chemical inhibitors such as wortmannin
and LY294002 or a dominant-negative mutant of the regula-
tory subunit p85K induces/stimulates the expression of iNOS
in LPS- or cytokine-stimulated C6 glial cells and rat primary
astrocytes [10], suggesting that activation of PI 3-kinase may
transduce an inhibitory signal for the expression of iNOS.
In this manuscript, we report that activation of PI 3-kinase
by expression of the catalytically active p110 subunit inhibits
the production of NO and the expression of iNOS in human
U373MG astrocytoma cells and primary astrocytes. These
results suggest that PI 3-kinase signal transduction pathway
is a negative regulator of the expression of iNOS in human
astrocytes.
2. Materials and methods
2.1. Reagents
Fetal bovine serum and DMEM/F-12 were from Gibco, USA. Hu-
man recombinant IL-1L, IFN-Q and TNF-K were purchased from
RpD, USA. Phosphatidylinositol and phosphatidylserine were pur-
chased from Matreya Inc., USA. Antibodies against regulatory sub-
unit of PI 3-kinase (p85K) and mouse macrophage iNOS were ob-
tained from Calbiochem, USA. [Q-32P]ATP (3000 Ci/mmol) was from
Amersham, USA.
2.2. Preparation of human astrocytes
Fetal CNS tissue was obtained from the Human Embryology Lab-
oratory, University of Washington, Seattle, WA, USA. The CNS
tissue from each fetal specimen was processed separately and inde-
pendently, as were subsequent cell cultures; there was no pooling of
CNS tissue from distinct fetal specimens. These cells were grown in a
serum-free, de¢ned medium (B16) enriched with 5 ng of basic ¢bro-
blast growth factor per ml for optimal growth of astrocytes and for
the suppression of ¢broblast growth [11]. By immuno£uorescence as-
say, these cultures homogeneously expressed GFAP. Cells were trypsi-
nized, subcultured and stimulated with cytokines in serum-free
DMEM/F-12. The human U373MG astrocytoma cell line was pur-
chased from the American Type Culture Collection.
2.3. Transfection of U373MG glial cells and human primary astrocytes
The cell monolayer (50^60% con£uent) was transfected by Lipofect-
amine Plus (Gibco, USA) following the manufacturer’s protocol. To
monitor the transfection e⁄ciency, cells were cotransfected with a
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pCAT 3-control plasmid (Promega, Madison, WI, USA). A radio-
isotopic method was used to assay CAT activity using a kit (Promega)
as described by the manufacturer’s protocol [10,12]. As revealed by
the CAT assay, transfection e⁄ciency ranged within 33^40% in
U373MG glial cells and within 38^44% in human primary astrocytes.
2.4. Assay of PI 3-kinase
Cells were lysed with ice-cold lysis bu¡er containing 1% v/v NP-40,
100 mM NaCl, 20 mM Tris (pH 7.4), 10 mM iodoacetamide, 10 mM
NaF, 1 mM sodium orthovanadate, 1 mM phenylmethyl sulfonyl
chloride and 1 Wg/ml of each of leupeptin, antipain, aprotinin and
pepstatin A. Lysates were incubated at 4‡C for 15 min, followed by
centrifugation at 13 000Ug for 15 min. The supernatant was pre-
cleared with protein G-Sepharose beads (Pharmacia Biotech Inc.)
for 1 h at 4‡C followed by the addition of 1 Wg/ml of p85K mono-
clonal antibody. After 2 h of incubation at 4‡C, protein G-Sepharose
beads were added and the resulting mixture was further incubated for
1 h at 4‡C. The immunoprecipitates were washed twice with lysis
bu¡er, once with phosphate-bu¡ered saline, once with 0.5 M LiCl,
100 mM Tris, pH 7.6, once in water, and once in kinase bu¡er (5 mM
MgCl2, 0.25 mM EDTA, 20 mM HEPES, pH 7.4). PI 3-kinase activ-
ity was determined as described earlier [10,13]. Brie£y, a lipid mixture
of 100 Wl of 0.1 mg/ml phosphatidylinositol and 0.1 mg/ml phospha-
tidylserine was dispersed by sonication in 20 mM HEPES, pH 7.0,
and 1 mM EDTA. The reaction was initiated by the addition of 20 WCi
of [Q-32P]ATP (3000 Ci/mmol) and 100 WM ATP and terminated after
15 min by the addition of 80 Wl of 1 N HCl and 200 Wl of chloro-
form:methanol (1:1). Phospholipids were separated by thin layer
chromatography and visualized by exposure to iodine vapor and auto-
radiography [10,13].
2.5. Assay for NO synthesis
Synthesis of NO was determined by assay of culture supernatant for
nitrite, a stable reaction product of NO with molecular oxygen, using
Griess reagent as described earlier [2^4].
2.6. Immunoblot analysis for iNOS
Cells were homogenized in 50 mM Tris^HCl (pH 7.4) containing
protease inhibitors (1 mM PMSF and 5 Wg/ml of each of aprotinin,
antipain, pepstatin A and leupeptin). After electrophoresis, the pro-
teins were transferred onto a nitrocellulose membrane, and the iNOS
band was visualized by immunoblotting with antibodies against
mouse macrophage iNOS and 125I-labeled protein A [3,4].
2.7. RNA isolation and Northern blot analysis
Total RNA was isolated using Ultraspec II RNA reagent (Biotecx
Laboratories Inc.) according to the manufacturer’s protocol. For
Northern blot analyses, 20 Wg of total RNA was electrophoresed on
1.2% denaturing formaldehyde-agarose gels, electrotransferred to
Hybond-Nylon Membrane (Amersham) and hybridized at 68‡C with
32P-labeled cDNA probe using Express Hyb hybridization solution
(Clontech) as described by the manufacturer. The cDNA probes
have been described earlier [3,4]. After hybridization, ¢lters were
washed two or three times in solution I (2USSC, 0.05% sodium do-
decyl sulfate (SDS)) for 1 h at room temperature followed by solution
II (0.1USSC, 0.1% SDS) at 50‡C for another hour. The membranes
were then dried and exposed to X-ray ¢lms (Kodak). The same
amount of RNA was hybridized with probe for actin.
2.8. Assay of transcriptional activity of NF-kB
To assay the transcriptional activity of NF-kB, cells were trans-
fected with pNF-kB-Luc, an NF-kB-dependent reporter construct
(obtained from Stratagene), using the Lipofectamine Plus method
[10,12]. After 24 h of transfection, cells were treated with di¡erent
stimuli for 12 h. Total cell extracts were used to measure luciferase
activity in a TD-20/20 Luminometer (Turner Designs, USA) using an
assay kit from Stratagene.
3. Results
3.1. Expression of a catalytically active p110 subunit of PI
3-kinase (p110*) inhibits the induction of NO production
in cytokine-stimulated human U373MG astrocytoma cells
PI 3-kinase consists of a catalytic subunit (p110) of 110 kDa
and a regulatory subunit (p85) of 85 kDa. In the constitutively
active mutant of PI 3-kinase (p110*), the inter-SH2 domain of
p85 is ligated to the NH2-terminus of p110 whereas in the
kinase-de¢cient mutant of p110 (p110-kd), the ATP binding
site is mutated [14]. It has been reported that expression of
p110* but not that of p110-kd is su⁄cient to promote Glut 4
translocation in adipocytes [14]. Therefore, to stimulate PI
3-kinase activity in human astrocytes, we transfected astro-
cytes with p110*. Fig. 1 shows that expression of the p110*
but not that of the p110-kd stimulated the lipid kinase activity
of PI 3-kinase. About a 2-fold increase in PI 3-kinase activity
was observed in cells transfected with 1 Wg of p110*. Then we
examined the regulation of iNOS expression by activation of
PI 3-kinase. Di¡erent combinations of proin£ammatory cyto-
kines induced the production of NO in U373MG glial cells
(Fig. 2A). Consistent to our earlier observation that inhibition
of PI 3-kinase by the expression of a dominant-negative mu-
tant of p85K induces/stimulates the expression of iNOS in rat
C6 glial cells [10], here we have observed that activation of PI
3-kinase by the expression of p110* inhibited the induction of
NO production in cytokine-stimulated U373MG glial cells
(Fig. 2A). However, the expression of p110-kd had no e¡ect
on the induction of NO production in cytokine-stimulated
cells. About 37^42% inhibition of NO production was found
in cells transfected with p110* compared to cells transfected
with p110-kd (Fig. 2A). To understand the mechanism of
Fig. 1. Expression of a catalytically active p110 subunit of PI 3-ki-
nase stimulates PI 3-kinase activity in human U373MG astrocytoma
cells. Cells plated at 50^60% con£uence in six-well plates were trans-
fected with 1 Wg of either p110* or p110-kd using Lipofectamine
Plus as described in Section 2. Control cells did not receive any
DNA but received only Lipofectamine and Plus reagents. 24 h after
transfection, cells were lysed, immunoprecipitated with monoclonal
antibodies against p85K, and the lipid kinase activity of immunopre-
cipitated PI 3-kinase was assayed as described under Section 2. Lip-
ids were detected by exposure to ¢lm at 370‡C (A) and lipid bands
corresponding to PI 3-P were quantitated by densitometry (B). Data
are from a single experiment representative of at least three others.
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p110*-mediated inhibition of NO production, we examined
the e¡ect of p110* on the protein level of iNOS by Western
blot analysis. Consistent to the inhibition of NO production,
p110* but not p110-kd inhibited the expression of iNOS pro-
tein (Fig. 2B) in cytokine-stimulated glial cells. Similarly,
p110* but not p110-kd also attenuated the expression of
iNOS mRNA in cells stimulated with the combination of
IL-1L and IFN-Q (Fig. 3). These results indicate that activa-
tion of PI 3-kinase provides an inhibitory signal for cytokine-
induced production of NO and expression of iNOS in human
astrocytes.
3.2. Expression of p110* does not inhibit the activation of
NF-kB in cytokine-stimulated U373MG cells
Proin£ammatory cytokine-induced expression of iNOS in
glial cells depends on the activation of NF-kB [3,4,10,12].
Therefore, to gain further insight into the mechanism of ac-
tion of activated PI 3-kinase, we investigated the e¡ect of
activation of PI 3-kinase on the activation of NF-kB. Activa-
tion of NF-kB was monitored by assaying the transcriptional
activity of NF-kB [10,12]. Cells were cotransfected with pNF-
kB-Luc, an NF-kB-dependent reporter construct, and either
p110* or p110-kd followed by the stimulation with proin£am-
matory cytokines. Proin£ammatory cytokines induced the ac-
tivation of NF-kB by about 4-fold as revealed from the lucif-
erase activity (Fig. 4). As expected, the expression of p110-kd
had no e¡ect on NF-kB-dependent reporter activity. How-
ever, in contrast to the inhibition of iNOS expression, p110*
did not inhibit NF-kB-dependent luciferase activity in cyto-
kine-stimulated cells (Fig. 4). Consistent to our earlier obser-
vation [15], vp21ras, a dominant-negative mutant of p21ras,
Fig. 2. Expression of p110* inhibits the induction of NO production
in cytokine-stimulated U373MG glial cells. Cells plated at 50^60%
con£uence in six-well plates were transfected with 1 Wg of either
p110* or p110-kd using Lipofectamine Plus. Control cells did not
receive any DNA but received only Lipofectamine and Plus re-
agents. 24 h after transfection, cells were stimulated with di¡erent
cytokines under serum-free conditions. (A) After 24 h of stimula-
tion, nitrite concentrations were measured in the supernatants. Data
are mean þ S.D. of three di¡erent experiments. (B) Cell homogenates
were electrophoresed, transferred on nitrocellulose membrane and
immunoblotted with antibodies against mouse macrophage iNOS as
described under Section 2. Concentrations of di¡erent stimuli were:
TNF-K, 10 ng/ml; IL-1L, 10 ng/ml; IFN-Q, 10 U/ml.
Fig. 3. E¡ect of p110* on the expression of iNOS mRNA in cyto-
kine-stimulated U373MG glial cells. Cells plated at 50^60% con£u-
ence in a 100 mm dish were transfected with 4 Wg of either p110*
or p110-kd using Lipofectamine Plus. Control cells did not receive
any DNA but received only Lipofectamine and Plus reagents. 24 h
after transfection, cells were stimulated with the combination of IL-
1L (10 ng/ml) and IFN-Q (10 U/ml). After 6 h of stimulation, cells
were taken out directly by adding Ultraspec II RNA reagent (Bio-
tecx Laboratories Inc.) to the plates for isolation of total RNA, and
Northern blot analysis for iNOS mRNA was carried out as de-
scribed in Section 2.
Fig. 4. E¡ect of p110* on the activation of NF-kB in cytokine-
stimulated U373MG glial cells. Cells plated at 50^60% con£uence in
six-well plates were cotransfected with 1 Wg of pNF-kB-Luc (an
NF-kB-dependent reporter construct) and 1 Wg of p110* or p110-kd
or vp21ras using Lipofectamine Plus. Control cells did not receive
any DNA but received only Lipofectamine and Plus reagents. After
24 h of transfection, cells were stimulated with di¡erent proin£am-
matory cytokines for 12 h. The expression of luciferase reporter was
quantitated as described in Section 2. Data are mean þ S.D. of three
di¡erent experiments. Concentrations of di¡erent stimuli were:
TNF-K, 10 ng/ml; IL-1L, 10 ng/ml; IFN-Q, 10 U/ml.
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inhibited NF-kB-dependent luciferase activity as a positive
experimental control (Fig. 4). These experiments suggest
that activation of PI 3-kinase inhibits the expression of
iNOS without inhibiting the activation of NF-kB.
3.3. Expression of p110* inhibits the expression of iNOS in
cytokine-stimulated human primary astrocytes
Human primary astrocytes have been shown to induce the
expression of iNOS in the presence of di¡erent proin£amma-
tory cytokines [15]. Since the activation of PI 3-kinase inhib-
ited the expression of iNOS in human U373MG astroglial
cells, we examined the e¡ect of p110* on cytokine-induced
expression of iNOS in human primary astrocytes. Di¡erent
combinations of TNF-K, IL-1L and IFN-Q induced the pro-
duction of NO (Fig. 5A) and the expression of iNOS protein
(Fig. 5B). However, expression of p110* but not that of p110-
kd attenuated cytokine-induced expression of production of
NO and expression of iNOS protein, suggesting that similar to
U373MG glial cells, activation of PI 3-kinase inhibits the in-
duction of iNOS in human primary astrocytes.
4. Discussion
The signaling events transduced by proin£ammatory cyto-
kines for the induction of iNOS are poorly understood. A
complete understanding of the cellular signaling mechanisms
involved in the induction of iNOS should identify novel tar-
gets for the therapeutic intervention in NO-mediated neuro-
in£ammatory and neurodegenerative diseases. In this study,
we overexpressed the catalytically active p110 subunit to in-
vestigate the role of PI 3-kinase in the induction of iNOS and
production of NO. Consistent to our earlier observation that
inhibition of PI 3-kinase stimulates or induces the expression
production of NO and the expression of iNOS in C6 glial cells
and rat primary astrocytes [10], we have found that activation
of PI 3-kinase inhibits the induction of NO production and
the expression of iNOS in U373MG glial cells and human
primary astrocytes.
Proin£ammatory cytokines (TNF-K, IL-1L or IFN-Q) bind
to their respective receptors and induce iNOS expression via
activation of NF-kB [10,12,16]. The presence of consensus
sequence in the promoter region of iNOS for the binding of
NF-kB [16] and the inhibition of iNOS expression with the
inhibition of NF-kB activation establish an essential role of
NF-kB activation in the induction of iNOS [3,4,10,12]. Acti-
vation of NF-kB by various cellular stimuli involves the pro-
teolytic degradation of IkBK and the concomitant nuclear
translocation of the liberated NF-kB heterodimer [17].
Although the biochemical mechanism underlying the degrada-
tion of IkBK remains unclear, it appears that various mitogens
and cytokines activate IKKs, kinases which phosphorylate
IkBK on serines 32 and 36 [18]. Upon phosphorylation,
IkBK which is still bound to NF-kB apparently becomes a
high a⁄nity substrate for an ubiquitin-conjugating enzyme
[19]. Following phosphorylation-controlled ubiquitination,
the IkBK is rapidly and completely degraded by the 20 S or
26 S proteosome and NF-kB heterodimer is targeted to the
nucleus [19]. Earlier, we have also observed that cAMP deriv-
atives that activate protein kinase A, mevalonate inhibitors
that inhibit the p21ras or antioxidants like N-acetyl cysteine
inhibit the expression of iNOS by inhibiting the activation of
NF-kB [3,4,20]. On the other hand, cell-permeable ceramide
analogs and inhibitors of protein phosphate 1/2A stimulate
the expression of iNOS in rat primary astrocytes by stimulat-
ing the activation of NF-kB [12,21]. However, recently, we
have found that inhibition of PI 3-kinase by either chemical
inhibitors or dominant-negative mutant of p85K stimulates/
induces the expression of iNOS in cytokine-stimulated rat
astrocytes without modulating cytokine-induced activation
of NF-kB, suggesting that PI 3-kinase-mediated regulation
of iNOS expression is independent of NF-kB activation. Con-
sistently, here we have demonstrated that activation of PI 3-
kinase by the expression of a catalytically active p110 subunit
inhibits the expression of iNOS in human astrocytes without
inhibiting the activation of NF-kB.
Recently, PI 3-kinase-associated signaling events have been
shown to prevent apoptosis in a number of cell types includ-
ing cerebellar granule neurons and hematopoietic cells [8,9].
Consistent with the apoptotic activity of NO [22] and the anti-
apoptotic activity of activated PI 3-kinase [8,9], the observed
attenuation of cytokine-induced expression of iNOS and pro-
duction of NO by activated PI 3-kinase in human astrocytes
indicates that the negative regulation of iNOS expression by
PI 3-kinase may contribute to its anti-apoptotic activity.
There are considerable evidences for the transcriptional in-
duction of iNOS (the high-output isoform of NOS) in the
CNS that is associated with autoimmune reactions, acute in-
Fig. 5. Expression of p110* inhibits the expression of iNOS in cyto-
kine-stimulated human primary astrocytes. Cells plated at 50^60%
con£uence in six-well plates were transfected with 1 Wg of either
p110* or p110-kd using Lipofectamine Plus. Control cells did not
receive any DNA but received only Lipofectamine and Plus re-
agents. 24 h after transfection, cells were stimulated with proin£am-
matory cytokines under serum-free conditions. (A) After 24 h of
stimulation, nitrite concentrations were measured in supernatants.
Data are mean þ S.D. of three di¡erent experiments. (B) Cell homo-
genates were immunoblotted with antibodies against mouse macro-
phage iNOS. Concentrations of di¡erent stimuli were: TNF-K,
10 ng/ml; IL-1L, 10 ng/ml; IFN-Q, 10 U/ml.
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fection and traumatic brain injury [5,7,22]. Once NO is
formed, it spontaneously reacts with O32 to form peroxynitrite
(ONOO3), the most reactive derivative of NO known so far
[23]. Both NO and peroxynitrite are potentially toxic mole-
cules to neurons and oligodendrocytes that may mediate tox-
icity through the formation of iron^NO complexes of iron-
containing enzyme systems [24], oxidation of protein sulfhy-
dryl groups [23], nitration of proteins, and nitrosylation of
nucleic acids and DNA strand breaks [25]. In the CNS,
iNOS is expressed mainly by activated astrocytes and micro-
glia, the two glial cell types involved in intracerebral immune
regulation. Astrocytes are the major glial cell population in
the CNS; therefore, induction of iNOS in astrocytes may be
an important source of NO in CNS in£ammatory disorders
associated with neuronal and oligodendrocytes death. There-
fore, activation of PI 3-kinase may represent an avenue for
therapeutic intervention in neuroin£ammatory and neurode-
generative disorders.
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